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Defects in mitophagy promote redox-driven
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Abstract
The metabolic syndrome covers metabolic abnormalities including
obesity and type 2 diabetes (T2D). T2D is characterized by insulin
resistance resulting from both environmental and genetic factors.
A genome-wide association study (GWAS) published in 2010 identi-
fied TP53INP1 as a new T2D susceptibility locus, but a pathological
mechanism was not identified. In this work, we show that mice
lacking TP53INP1 are prone to redox-driven obesity and insulin
resistance. Furthermore, we demonstrate that the reactive oxygen
species increase in TP53INP1-deficient cells results from accumula-
tion of defective mitochondria associated with impaired PINK/
PARKIN mitophagy. This chronic oxidative stress also favors accu-
mulation of lipid droplets. Taken together, our data provide
evidence that the GWAS-identified TP53INP1 gene prevents meta-
bolic syndrome, through a mechanism involving prevention of
oxidative stress by mitochondrial homeostasis regulation. In
conclusion, this study highlights TP53INP1 as a molecular regulator
of redox-driven metabolic syndrome and provides a new preclinical
mouse model for metabolic syndrome clinical research.
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Introduction
Metabolic syndrome (MS) describes a cluster of metabolic abnor-
malities including obesity, insulin resistance, hypertension and
dyslipidemia (Pothiwala et al, 2009). The prevalence of MS has
been increasing exponentially in the last few decades, paralleling
the obesity epidemic. Obesity, which is defined as a body mass
index ≥ 30 kg/m2, results from accumulation of white adipose
tissue. It depends on both genetic and environmental factors, in
particular lifestyles featuring increased nutrient caloric intake
but decreased calorie consumption. Diet may have a major role
in the pathogenesis and prevalence of obesity (Calder et al, 2011),
but other causes have to be considered, such as gut microbiota
which affect host nutritional metabolism (Musso et al, 2010; Greiner
& Backhed, 2011), and lack of physical exercise (Calder et al, 2011).
Excess body weight is a major public health concern since it is asso-
ciated with increased risk of cardiovascular disease, type 2 diabetes
(T2D), Alzheimer’s disease and cancer (van Kruijsdijk et al, 2009;
Siegel & Zhu, 2009; Forte et al, 2012; Leboucher et al, 2013).
One major link between obesity and associated diseases is
the chronic low-grade inflammatory state observed in obese
patients (Calder et al, 2011; Gregor & Hotamisligil, 2011). Inflam-
mation is induced by excessive accumulation of lipids in adipose
tissue leading to adipocyte stress and release of inflammatory
cytokines and adipokines. The resulting recruitment of immune
cells to key metabolic organs further contributes to chronic inflam-
mation. Obesity-associated immune signals concern all types of
immune cells that prompt inflammation, as well as adipocytes
themselves (Chawla et al, 2011; Deng et al, 2013). Importantly, the
1 Inserm, U1068, CRCM, Marseille, France
2 Institut Paoli-Calmettes, Marseille, France
3 Aix-Marseille Université, Marseille, France
4 CNRS, UMR7258, CRCM, Marseille, France
5 Inserm, U1069, Nutrition, Croissance et Cancer (N2C), Tours, France
6 CNRS, UMR5203, Inserm, U661, Universités de Montpellier 1 & 2, IGF, Montpellier, France
7 Inserm, U1065, C3M, Team 8 “Hepatic Complications in Obesity”, Nice, France
8 Université de Nice-Sophia-Antipolis, Nice, France
9 Centre Hospitalier Universitaire de Nice, Pôle Digestif, Hôpital L’Archet, Nice, France
10 Cell Biology, Department of Medicine, Imperial College, London, UK
11 Islet Cell Laboratory, University of Pisa – Cisanello Hospital, Pisa, Italy
*Corresponding author. Tel: +33 4 91 82 88 29; Fax: +33 4 91 82 60 83; E-mail: alice.carrier@inserm.fr
EMBO Molecular Medicine Vol 7 | No 6 | 2015 ª 2015 The Authors. Published under the terms of the CC BY 4.0 license802
obesity-associated chronic low-grade inflammatory state impacts
all organs in the body. Hence, obese patients are at increased risk
of developing cancer in any localization even if pancreatic and
liver cancers show the highest increase in risk (Siegel & Zhu,
2009).
Inflammation is associated with oxidative stress which is
one obesity-related feature participating in the development of
MS (Bondia-Pons et al, 2012; Khoo et al, 2012; Rolo et al, 2012;
Crujeiras et al, 2013). Oxidative stress results from excess of reac-
tive oxygen species (ROS) production overwhelming antioxidant
defenses (Pouyet & Carrier, 2010). ROS are mainly produced as
by-products of the mitochondrial electron transport chain involved
in ATP production (oxidative phosphorylation). Excess fatty acids
and glucose are known to be deleterious for mitochondrial func-
tion, thus increasing ROS production. ROS can oxidize cell macro-
molecules, leading to impaired cellular homeostasis and associated
pathologies such as cancer (Gupta et al, 2012; Crujeiras et al,
2013).
In the recent years, we have provided evidence that tumor
protein 53-induced nuclear protein 1 (TP53INP1) is a key stress
protein with antioxidant-associated tumor suppressive function
(Gironella et al, 2007; Gommeaux et al, 2007; Cano et al, 2009;
N’Guessan et al, 2011; Seux et al, 2011). The TP53INP1 gene (a
transcriptional target of p53 and other transcription factors) is
highly conserved between human and rodents and over-expressed
during stress response including inflammation (Tomasini et al,
2001; Jiang et al, 2004). TP53INP1-deficient mice, which lack partici-
pation of TP53INP1 in stress resolution, are prone to stress-induced
dysfunctions including cancer (Gironella et al, 2007; Gommeaux
et al, 2007; Cano et al, 2009; N’Guessan et al, 2011). Moreover,
these mutant mice show a chronic oxidative stress characterized
by an increase in the cell ROS level as well as a decrease of
antioxidant defenses (Gommeaux et al, 2007; Cano et al, 2009;
N’Guessan et al, 2011). Restoration of TP53INP1 expression in
TP53INP1-deficient cells rescues the phenotype by alleviating ROS
burden (Cano et al, 2009).
We demonstrated that TP53INP1 impacts on p53 and p73 trans-
criptional activity by direct interaction and mediates the antioxidant
activity of p53 (Tomasini et al, 2003, 2005; Cano et al, 2009).
The tumor suppressor p53 is a fascinating protein endowed with
multiple functions, including metabolic regulation, in common
with two other members of this family: p63 and p73 (Maddocks &
Vousden, 2011; Rufini et al, 2012; Su et al, 2012; Liang et al,
2013). We also provided evidence for a role of TP53INP1 in auto-
phagy by direct interaction with mammalian Atg8 orthologs includ-
ing LC3 (Seillier et al, 2012). Autophagy is a catabolic process
involved in the cellular energetic balance and lipid homeostasis
thus regulating obesity (Singh & Cuervo, 2011; Lavallard et al,
2012). Interestingly, a genome-wide association study (GWAS)
published in 2010 identified TP53INP1 as a new T2D susceptibility
locus (Voight et al, 2010). Collectively, those observations led us
to address the role of TP53INP1 in metabolic regulation. We used
TP53INP1-deficient mice to assess in vivo the effect of a high-fat
diet which favors obesity, insulin resistance and T2D, and we
investigated the cellular metabolic defects induced by TP53INP1
deficiency. In this work, we provide the demonstration that
TP53INP1 is a primary molecular link between oxidative stress
and MS.
Results
Absence of TP53INP1 favors obesity in a redox-dependent
manner in vivo
We initially observed that the body weight of 5-month-old
TP53INP1-deficient (KO or /) mice was higher than WT (+/+) in
both males and females (Supplementary Fig S1A) and that fat mass
was more abundant in TP53INP1-deficient than in WT mice
(Supplementary Fig S1B). We supplemented drinking water with the
anti-oxidant N-acetylcysteine (NAC) which alleviates chronic oxida-
tive stress associated with TP53INP1 deficiency through increase of
intracellular glutathione level (Cano et al, 2009; N’Guessan et al,
2011). NAC supplementation completely abolished fat mass differ-
ence between TP53INP1-deficient and WT mice (Supplementary Fig
S1A and B). We then fed 8-week-old mice with a high-fat diet (HFD,
60% fat) (control (CTRL) food is 10% fat) during 16 weeks. We
observed a higher body weight gain in HFD-fed TP53INP1 KO than
WT mice (Fig 1A and Supplementary Fig S2A), although food
consumption did not differ between genotypes (Supplementary
Fig S3). Epididymal and renal fat masses were higher in KO than in
WT mice upon HFD (Fig 1B and Supplementary Fig S2A). HFD-
induced liver weight increase was also higher in HFD-fed TP53INP1
KO mice than WT (Fig 1B and Supplementary Fig S2A). HFD-
induced steatosis (accumulation of lipid droplets in hepatocytes),
assessed by histological analysis, was greater in KO than in WT
mice (Supplementary Fig S2B). Taken together, those data show
that TP53INP1-deficient mice are prone to obesity and liver compli-
cations, suggesting a role of TP53INP1 in dampening fat storage.
Interestingly, the gene encoding TP53INP1 was over-expressed in
the liver of HFD-fed C57BL/6 mice (Supplementary Fig S2C).
Furthermore, in human, morbidly obese patients with hepatic stea-
tosis showed an increase in hepatic TP53INP1 expression, and
TP53INP1 expression was correlated with the level of a marker of
hepatocyte death (keratin 18), with the grade of steatosis and with
the expression level of the stress marker NQO1 (Supplementary Fig
S2D–H and Supplementary Table S2). This suggests that TP53INP1
expression is induced as part of an obesity-associated stress
response and that this protective function is lacking in TP53INP1-
deficient mice, thus impairing fat homeostasis.
In order to evaluate the impact of chronic oxidative stress in
obesity predisposition of TP53INP1 KO mice, we treated the mice
with NAC at the starting of HFD. Whereas NAC treatment did
not modify final weight gain in HFD-fed WT mice, it completely
abolished all body weight, organ weight and hepatic steatosis
differences between HFD-fed KO and WT mice, bringing the KO
mice values to those of the WT (Fig 1 and Supplementary Fig S2B).
These results illustrate that chronic oxidative stress affecting the
TP53INP1-deficient mice predisposes them to increased weight gain
and adiposity, further favoring obesity and hepatic steatosis when
challenged with a lipid-rich diet.
Insulin resistance establishment is elicited by chronic oxidative
stress induced by TP53INP1 deficiency in vivo
As obesity is generally associated with insulin resistance (IR), we
investigated the susceptibility of HFD-fed TP53INP1-deficient
mice to develop IR, glucose intolerance and hyperinsulinemia. We
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monitored glycemia and insulinemia at the beginning and end of
HFD protocol and determined the HOMA-IR index (Fig 2A and B,
respectively, and Supplementary Table S1). We also performed
glucose tolerance (GTT) and insulin tolerance (ITT) tests at the end
of HFD protocol (Fig 2C and D, respectively). In HFD-fed WT
animals, glucose utilization (GTT, Fig 2C) and insulin sensitivity
(ITT, Fig 2D) were both altered as expected. This was compensated
by hyperinsulinemia (Fig 2B), while blood glucose remained
A
B
W
ei
gh
t (
g)
W
ei
gh
t (
g)
TP53INP1 +/+ CTRL n=12 
TP53INP1 -/- CTRL n=12 
TP53INP1 +/+ HFD n=11 
TP53INP1 -/- HFD n=12 
TP53INP1 +/+ CTRL NAC n=6 
TP53INP1 -/- CTRL NAC n=6 
TP53INP1 +/+ HFD NAC n=5 
TP53INP1 -/- HFD NAC n=6 
 No NAC  NAC
TP53INP1 +/+ HFD n=5  
TP53INP1 -/- HFD n=6  
TP53INP1 +/+ CTRL n=6  
TP53INP1 -/- CTRL n=6  
TP53INP1 +/+ CTRL NAC n=6 
TP53INP1 -/- CTRL NAC n=6  
TP53INP1 +/+ HFD NAC n=5  
TP53INP1 -/- HFD NAC n=6  
20 
25 
30 
35 
40 
45 
50 
20
25
30
35
40
45
50
Liver Epididymal
fat mass 
Renal fat
mass 
O
rg
an
 w
ei
gh
t  
(g
)
§§
£ 
0.5 
1 
1.5 
2 
2.5 
3 
3.5 
0 
0 5 10 15 0 5 10 15
£ £ 
££££ 
** 
* 
§§
£ £ 
££££ 
*
£ 
§
§
£ £ 
££ 
* 
££ 
* * * * * * * * * * 
* * 
)skeew(emiT)skeew(emiT
Figure 1. TP53INP1-deficient mice are highly susceptible to HFD-induced obesity owing to their chronic oxidative stress.
TP53INP1-KO (/) and WT (+/+) male mice were subjected to a high-fat diet (HFD, 60% fat) or a control diet (CTRL) for 16 weeks. Mice drank tap water or tap water
supplemented with NAC (10 mg/ml or 1%).
A Curves show mice body weight recorded every week. CTRL: P (/ versus +/+; t = 8w) = 0.047; P (/ versus +/+; t = 9w) = 0.023. HFD: P (/ versus +/+;
t = 7w) = 0.039; P (/ versus +/+; t = 8w) = 0.029; P (/ versus +/+; t = 9w) = 0.021; P (/ versus +/+; t = 10w) = 0.014; P (/ versus +/+;
t = 11w) = 0.0046; P (/ versus +/+; t = 12w) = 0.0028; P (/ versus +/+; t = 13w) = 0.0025; P (/ versus +/+; t = 14w) = 0.00051; P (/ versus +/+;
t = 15w) = 0.00027; P (/ versus +/+; t = 16w) = 0.00013.
B At the end of protocol, mice were sacrificed; liver and epididymal and renal fat masses were taken and weighed. Histograms show organ weight. Liver: P (/ versus
+/+; HFD) = 0.014; P (HFD versus CTRL; +/+) = 0.00063; P (HFD versus CTRL; /) = 0.0010; P (HFD versus CTRL; +/+ NAC) = 0.034; P (HFD versus CTRL;
/ NAC) = 0.027; P (NAC versus no NAC; / HFD) = 0.014. Epididymal fat mass: P (/ versus +/+; HFD) = 0.011; P (HFD versus CTRL; +/+) = 0.028; P (HFD versus
CTRL; /) = 0.000017; P (HFD versus CTRL; +/+ NAC) = 0.019; P (HFD versus CTRL; / NAC) = 0.0054; P (NAC versus no NAC; +/+ CTRL) = 0.037; P (NAC versus no
NAC; / HFD) = 0.0025. Renal fat mass: P (/ versus +/+; HFD) = 0.0041; P (HFD versus CTRL; +/+) = 0.028; P (HFD versus CTRL; /) = 0.000013;
P (HFD versus CTRL; +/+ NAC) = 0.019; P (HFD versus CTRL; / NAC) = 0.0078; P (NAC versus no NAC; / HFD) = 0.0047.
Data information: Results are expressed as the mean  SEM and are representative of two independent experiments. * / versus +/+; £ HFD versus CTRL; § NAC versus
no NAC; 1 character: P < 0.05; 2 characters: P < 0.005; 4 characters: P < 0.00005.
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unchanged (Fig 2A), indicating that WT mice under HFD have devel-
oped IR. Interestingly, TP53INP1 knockout mice fed a standard diet
were also glucose intolerant and insulin resistant, but neither hyper-
glycemic nor hyperinsulinemic. Glucose intolerance and IR further
developed when TP53INP1-deficient mice were fed a HFD, and hyper-
insulinemia finally occurred in such experimental conditions with
plasma insulin levels twice as high in HFD-fed TP53INP1-deficient as
in WT animals. As a consequence, the combined effects of HFD-
induced obesity and the absence of TP53INP1 led to hyperglycemia
(Fig 2A and C), suggesting that these mice had developed T2D. In
contrast, NAC-treated HFD-fed TP53INP1-deficient mice showed similar
metabolic profiles to HFD-fed WT animals (Fig 2A and B) indicative of
chronic oxidative stress predisposing those mice to systemic IR, hyper-
insulinemia, glucose intolerance and therefore T2D.
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Figure 2.
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TP53INP1 mRNA has been reported to be present in human islets
of Langerhans (~30th centile) (Eizirik et al, 2012). Using immunoflu-
orescence to examine mouse pancreatic sections and human
isolated b-cells (Fig 3A and B), and quantitative PCR analysis of
rodent cells and endocrine tissues (Fig 3C and D), we found that
TP53INP1 was expressed both by pancreatic exocrine cells and by
the insulin-secreting b-cells which play a central role in the control
of glucose homeostasis. Because TP53INP1-deficient mice were
glucose intolerant, and since TP53INP1 transcripts were significantly
increased in islets isolated from HFD-fed mice (Fig 3E), we next
hypothesized that defects in b-cell function or plasticity could occur
in TP53INP1 knockout mice. However, neither functional modifica-
tions (glucose-induced insulin secretion, NADP(H) or cytosolic free
calcium concentration, [Ca2+]c) nor changes in islet mass were
detected in the absence of TP53INP1 (Supplementary Fig S4). These
results suggest that HFD-fed TP53INP1 KO mice developed diabetes
due to severe IR, which resulted from whole-body redox deregula-
tion rather than specific endocrine pancreatic alterations. Nonethe-
less, the observed failure of b-cell mass or function to increase in
response to elevated insulin demand suggests that TP53INP1
may also be required in b-cells to mount a compensatory response
to IR.
Mitochondrial number is increased in the absence of TP53INP1,
promoting chronic oxidative stress
As susceptibility to obesity and T2D in TP53INP1-deficient mice is
redox-linked, we addressed the question of the cellular origin of
chronic oxidative stress in these mice (Gommeaux et al, 2007;
Cano et al, 2009; N’Guessan et al, 2011). Oxidative stress could be
due to ROS over-production in mitochondria which are the main
source of ROS since superoxide is a by-product of respiratory chain
(Murphy, 2009). We stained WT and TP53INP1-deficient cells
(immortalized MEFs, depicted as MEFi in this manuscript) with a
mitochondrial superoxide stain (MitoSox) and observed a fourfold
higher level of staining in deficient cells compared to WT by flow
cytometry analysis (Fig 4A). Co-staining with the MitoTrackerTM
marker also showed that the mitochondrial mass was threefold
higher in TP53INP1 KO cells than in WT (Fig 4B). Normalization
of MitoSox to MitoTracker staining (Fig 4C) suggests that the
increased mitochondrial mass is not the sole cause of ROS
increase. Transmission electron microscopy (TEM; Fig 4D and E)
revealed a higher number of mitochondria in TP53INP1-deficient
cells than in WT. This difference was not affected by H2O2
(oxidative stress) treatment, suggesting that increase in mitochon-
drial number is the cause and not the consequence of chronic
oxidative stress in the absence of TP53INP1. Together, those data
demonstrate an increase in both mitochondrial number and
ROS-producing activity in the absence of TP53INP1.
Increased mitochondrial number in the absence of TP53INP1
stems from impaired mitophagy of dysfunctional
mitochondrial pool
We previously provided evidence for impaired autophagy in
TP53INP1-deficient cells (N’Guessan et al, 2011; Seillier et al,
2012). Therefore, we addressed the possibility that dysregulation of
the mitochondrial compartment might stem from the impaired elimi-
nation of damaged mitochondria by mitophagy. Treatment of MEFi
with the autophagy inhibitor 3-MA (which blocks autophagy at
early stage) led to both increased MitoSox and MitoTracker staining
in WT cells (Fig 4A–C). Remarkably, this increase was not observed
in TP53INP1-deficient cells, suggesting that autophagic flow leading
to mitophagy must be chronically impaired in these cells. To gain
further insight into this issue, we quantified the number of mitophagic
vacuoles in MEFi. Figure 4D and E clearly show the presence of
autophagic vacuoles containing mitochondria (entire or almost
degraded) in TP53INP1 KO cells, whereas very few of these struc-
tures were seen in WT counterparts. As no change in mitochondrial
mass was observed after autophagy inhibition in TP53INP1-deficient
cells, this accumulation of mitophagic structures suggests a block-
ade of late stages in the mitophagic process, for example, fusion of
Figure 2. TP53INP1-deficient mice have moderate redox-related insulin resistance syndrome which is exacerbated by HFD protocol.
Male TP53INP1 KO andWTmice were fed a high-fat diet (HFD, 60% fat) or a control diet (CTRL) during 16 weeks. Mice drank tap water or NAC-supplemented tap water (1%).
A, B Histograms show blood glucose (A) or plasma insulin (B) levels of 6-h-fasted mice at the beginning (Week 0) and/or at the end of the protocol (Week 16). Fasting
blood glucose week 16: P (/ versus +/+; HFD) = 0.0052; P (CTRL versus HFD; /) = 0.000081; P (NAC versus no NAC; / HFD) = 0.0019; P (w16 versus w0;
+/+ CTRL) = 0.012; P (w16 versus w0; / CTRL) = 0.050; P (w16 versus w0; / HFD) = 0.0023. Fasting plasma insulin: P (/ versus +/+; HFD) = 0.043; P (CTRL
versus HFD; +/+) = 0.028; P (CTRL versus HFD; /) = 0.013; P (CTRL versus HFD; +/+ NAC) = 0.011; P (CTRL versus HFD; / NAC) = 0.0015; P (NAC versus no
NAC; / HFD) = 0.038.
C Glucose tolerance test (GTT) was performed on 6-h-fasted mice during 120 min after injection of 1 g glucose/kg of body weight. Curves on the left show blood
glucose level monitored after injection of glucose. Histograms on the right show area under curve (AUC). Fasting blood glucose: P (/ versus +/+; CTRL;
t = 0 min) = 0.045; P (/ versus +/+; CTRL; t = 15 min) = 0.013; P (/ versus +/+; CTRL; t = 30 min) = 0.016; P (/ versus +/+; CTRL; t = 60 min) = 0.030;
P (/ versus +/+; CTRL; t = 90 min) = 0.017; P (/ versus +/+; HFD; t = 60 min) = 0.041; P (/ versus +/+; HFD; t = 90 min) = 0.043; P (/ versus +/+; HFD;
t = 120 min) = 0.034; P (HFD versus CTRL; +/+; t = 15 min) = 0.0076; P (HFD versus CTRL; +/+; t = 30 min) = 0.0067; P (HFD versus CTRL; +/+;
t = 60 min) = 0.00058; P (HFD versus CTRL; +/+; t = 90 min) = 0.0010; P (HFD versus CTRL; +/+; t = 120 min) = 0.023; P (HFD versus CTRL; /;
t = 60 min) = 0.032. AUC: P (/ versus +/+; CTRL) = 0.023; P (/ versus +/+; HFD) = 0.035; P (HFD versus CTRL; +/+) = 0.042.
D Insulin tolerance test (ITT) was performed on 6-h-fasted mice during 150 min after injection of 0.70 U insulin/kg of body weight. Curves on the left show blood
glucose level monitored after injection of insulin. Histograms on the right show area above curve (AAC). Fasting blood glucose: P (/ versus +/+; CTRL;
t = 15 min = 0.012; P (/ versus +/+; CTRL; t = 30 min) = 0.022; P (/ versus +/+; HFD; t = 0 min) = 0.027; P (/ versus +/+; HFD; t = 15 min) = 0.011;
P (/ versus +/+; HFD; t = 30 min) = 0.0037; P (/ versus +/+; HFD; t = 60 min) = 0.0028; P (/ versus +/+; HFD; t = 90 min) = 0.041; P (/ versus +/+;
HFD; t = 120 min) = 0.0032; P (/ versus +/+; HFD; t = 150 min) = 0.0025; P (HFD versus CTRL; +/+; t = 15 min) = 0.0082; P (HFD versus CTRL; +/+;
t = 30 min) = 0.033; P (HFD versus CTRL; +/+; t = 90 min) = 0.047; P (HFD versus CTRL; +/+; t = 150 min) = 0.028; P (HFD versus CTRL; /; t = 15 min) = 0.026;
P (HFD versus CTRL; /; t = 30 min) = 0.0095; P (HFD versus CTRL; /; t = 60 min) = 0.0031; P (HFD versus CTRL; /; t = 90 min) = 0.033; P (HFD versus
CTRL; /; t = 120 min) = 0.0068; P (HFD versus CTRL; /; t = 150 min) = 0.0082. AAC: P (/ versus +/+; HFD) = 0.030; P (HFD versus CTRL; /) = 0.037.
Data information: Results are expressed as the mean  SEM and are representative of two independent experiments. * TP53INP1 / versus TP53INP1 +/+; £ HFD
versus CTRL; $ Week 16 versus Week 0; § NAC versus no NAC; 1 character: P < 0.05; 2 characters: P < 0.005; 4 characters: P < 0.00005.
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autophagosomes with lysosomes, rather than increased mitophagic
flow. These results were unchanged after H2O2 treatment, suggest-
ing that oxidative stress observed in the absence of TP53INP1 was
the consequence and not the cause of a defect in mitochondria
degradation. Higher number of mitophagic structures in TP53INP1
KO cells than in WT was also indicated by LC3/mitotracker
co-labeling and quantification by confocal fluorescence microscopy
(Supplementary Fig S5).
Western blot analysis performed on MEFi lysates (Fig 5A)
showed higher levels of VDAC1, consistent with increased mito-
chondrial mass in TP53INP1 KO MEFi. By contrast, PINK1 and
PARKIN levels were lowered in the absence of TP53INP1. As both
PINK1 and PARKIN proteins are necessary for PINK/PARKIN-mediated
mitophagy (following a loss of mitochondrial potential membrane in
defective mitochondria) (Novak, 2012), this result is consistent with
defective mitochondrial degradation by mitophagy. Neither oxida-
tive stress nor antioxidant treatment (H2O2 and NAC treatment,
respectively) impacted the lowered PINK1 and PARKIN levels in KO
cells (Fig 5A). Surprisingly, BNIP3 and NIX protein levels were
increased in TP53INP1 KO cells compared to WT, suggesting
that hypoxia-induced mitophagy, which implicates BNIP3 and NIX
(Zhang & Ney, 2009), was not affected in TP53INP1-deficient cells.
Lower PINK1 and PARKIN levels in the absence of TP53INP1 were
also observed in vivo in mitochondria-enriched fractions from
mouse liver (Fig 5C right). Nevertheless, the clear decrease in
PINK1/PARKIN level and increase in VDAC level in TP53INP1 /
cells (Fig 5A) were not totally recapitulated in the mice total liver
lysates (Fig 5C left).
To gain insights into possible molecular partnerships between
TP53INP1 and proteins involved in mitophagy, we performed
immunoprecipitation assays. This provided further evidence for
a direct interaction between each of the TP53INP1 isoforms
(TP53INP1a or TP53INP1b) and both PINK1 and PARKIN, but not
with BNIP3 or NIX (Fig 5B). Interestingly, Fig 5C shows detection
of TP53INP1 in mitochondria-enriched fractions from WT liver,
thus demonstrating a mitochondrial sub-cellular localization of
TP53INP1, in addition to its known nucleo-cytoplasmic localization
(Tomasini et al, 2001; Seillier et al, 2012). Moreover, restoration
of TP53INP1 expression induced an increase in the level of both
PINK1 and PARKIN in the mitochondrial fraction and confirmed
localization of TP53INP1 to mitochondria (Supplementary Fig S6A).
Finally, we observed a decreased level of PGC-1a (a regulator of
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mitochondrial biogenesis and function) in TP53INP1-deficient cells
compared to WT (Fig 5A), suggesting that mitochondrial accumula-
tion in the absence of TP53INP1 does not rely on increased mito-
chondrial biogenesis. (We cannot exclude the possibility that the
absence of TP53INP1 rather negatively impacts on mitochondrial
biogenesis.) Taken together, these data suggest that (i) at least large
in part, accumulation of mitochondria in TP53INP1-deficient cells
results from a mitophagic defect and (ii) that TP53INP1 is able to
participate in the completion of PINK/PARKIN-dependent mito-
phagy by direct physical interaction with these proteins.
As part of mitochondrial ROS production was not related to
an increase in mitochondrial mass (Fig 4C), we assessed whether
mitochondrial over-production of ROS may be due to dysfunctional
mitochondria. Mitochondrial oxygen consumption analysis showed
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decreased oxygen flow in TP53INP1-deficient MEFi compared to
WT, both in permeabilized and in intact cells, and whatever the
substrate used (glucose versus lipid-related substrate) in the
permeabilized cell setting (Fig 6A–C). Thus, the oxidative phosphory-
lation system of TP53INP1 KO MEFi is impaired compared to WT,
probably resulting from specific mitochondrial alterations as similar
observations were made in intact and permeabilized cells.
Decreased oxygen consumption in the setting of lipid substrates
(Fig 6C) is probably not related to decreased substrate availability
since levels of CPT1A and CPT1B (two isoforms of CPT1, the key
enzymes responsible for the mitochondrial uptake of long-chain
fatty acids for beta-oxidation) did not differ between KO MEFi and
WT cells (Fig 6E). Analysis of respiratory chain complexes showed
decreased activity of complex IV (Fig 6D), without any change in
complex expression as quantified by Western blotting (L. Peyta,
S. Servais, unpublished data). Finally, analysis of mitochondrial
shape and size by transmission electron microscopy (TEM; Fig 4D
and E) showed that upon H2O2 treatment, mitochondria became
bigger (longer) in WT cells probably as a result of stress-induced
mitochondrial fusion. By contrast, mitochondria occupied a smaller
surface in H2O2-treated TP53INP1 KO cells, suggesting an impaired
ability of TP53INP1-deficient mitochondria to cope with stress.
Collectively, our data show accumulation of defective mitochon-
dria within TP53INP1-deficient MEFi associated with impaired mito-
phagy. The cumulative effect of increased mitochondrial number
and their dysfunctional state is likely at the origin of ROS over-
production and chronic oxidative stress observed in the absence of
TP53INP1.
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Accumulation of lipid droplets is linked with oxidative stress in
TP53INP1-deficient cells
TEM analysis of MEFs revealed a huge number of lipid droplets (LD)
in TP53INP1-deficient MEFi, whereas these were absent from control
MEFs (Fig 7A). Staining of these LD using the fluorescent Bodipy
compound (Fig 7B, left panel) confirmed that TP53INP1 KO MEFs
contain far more LD than WT cells. To assess whether this feature
could be linked to increased ROS production in deficient cells, we
analyzed LD in H2O2-treated cells (Fig 7A and B). Upon oxidative
stress, WT cells showed a striking increase in LD number which was
not observed in TP53INP1 KO cells. Reciprocally, we treated cells
with the antioxidant NAC (Fig 7B) and observed a reduction in LD
number in both genotypes. Results obtained in primary MEFs corrob-
orate those in MEFi (Supplementary Fig S7), showing that what we
observed in MEFi is directly linked to the absence of TP53INP1 and
not immortalization event(s). This study thus shows that oxidant
treatment increases LD number in WT cells but, conversely, antioxi-
dant treatment reduces LD number in TP53INP1 KO cells, both treat-
ments abolishing differences existing between WT and KO cells. To
gain molecular insight into these metabolic alterations, and based
on a transcriptomic analysis of MEFi KO cells compared to WT
(M. Seillier, A. Carrier, unpublished data), we showed by Western
blotting an over-expression of PPARc in KO cells, while expression of
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b-catenin was decreased (Fig 7C). It is known that the Wnt/b-catenin
pathway (canonical Wnt pathway) inhibits expression of the gene
coding PPARc, a positive regulator of adipo- and lipogenesis. Consis-
tently, treatment with a PPARc inhibitor (GW-9662) prevented LD
accumulation, whereas treatment with a Wnt/b-catenin pathway
inhibitor (PNU-74654) induced LD formation in both genotypes
(Fig 7B), suggesting that regulation of PPARc expression by canoni-
cal Wnt pathway is directly involved in LD accumulation in
TP53INP1 KO cells. Finally, restoration of TP53INP1 expression led
to decreased PPARc expression (Supplementary Fig S6B) as well as
decreased accumulation of LD (Supplementary Fig S6C). Western
blotting analysis also showed decreased expression of lipases (ATGL
and MGLL) in the absence of TP53INP1 (Fig 7C), in agreement with
increased LD content in MEFi KO cells. Taken together, those data
provide molecular insights into redox-linked lipid metabolism
defects in the absence of TP53INP1. We can conclude from these
experiments that chronic oxidative stress observed in TP53INP1-defi-
cient cells is at the origin of the accumulation of LD, which are likely
involved in the in vivo increased fat depot and hepatic steatosis asso-
ciated with HFD-induced obesity.
Discussion
This work addresses the function of TP53INP1 as a T2D suscepti-
bility gene as proposed 5 years ago (Voight et al, 2010; Cauchi
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et al, 2012) and provides both the demonstration and a mecha-
nism for this function. We should note, however, that at present
there is no evidence that the TP53INP1 locus is associated with
obesity in man. Nonetheless, in our mouse model, the absence of
TP53INP1 favors increased body weight and fat mass, most
spectacularly in an experimental setting of obesity induced by
lipid-rich diet. Use of an antioxidant treatment, which alleviates
the chronic oxidative stress affecting TP53INP1-deficient animals
(N’Guessan et al, 2011), completely abolishes the predisposition
to obesity, demonstrating that oxidative stress is the cause of
exacerbated obesity in these animals. The present data thus
provide the novel finding that oxidative stress may also be the
cause of obesity and not only the well-known consequence of a
chronic low-grade inflammatory state associated with obesity. By
its action on redox status homeostasis, TP53INP1 is thus a new
molecular actor of obesity prevention, and the current work thus
adds to the knowledge of the molecular events involved in obesity
predisposition.
We also observed that a lipid-rich diet reinforces the predis-
position of TP53INP1-deficient mice to IR. Indeed, basal glycemia
and insulinemia are high in obese (HFD-fed) TP53INP1-deficient
mice, this feature being completely prevented by antioxidant treat-
ment showing a key role of oxidative stress. Additionally, glycemia
of obese TP53INP1-deficient mice is barely affected after insulin
injection in the ITT experimental setting. Interestingly, glycemia of
CTRL-fed TP53INP1-deficient mice follows the same curve as HFD-
fed WT mice, suggesting that absence of TP53INP1 by itself favors IR
usually related to obesity. Thus, emergence of IR in TP53INP1
mutant mice appears to result from chronic oxidative stress, without
a requirement for increased adiposity. Adiposity may nonetheless
strengthen the effects of the existing oxidative stress and IR, a novel
observation of the current work. Importantly, our studies provide
evidence, through the generation of animal model, of the molecular
mechanisms through which the TP53INP1 gene influences T2D
predisposition in man (Voight et al, 2010). Intriguingly, our data
suggest that antioxidants may be of use in individuals with T2D
variants at the TP53INP1 locus that affect diabetes risk.
We note that the variant at the TP53INP1 locus on chromosome
8 (rs896854, lying in intron 1) associated with T2D in GWAS studies
(Voight et al, 2010) appears to lead to impaired b-cell function (i.e.
reduced insulin secretion), as measured by a decrease in HOMA-B
(Voight et al, 2010) and unchanged insulin sensitivity. Moreover,
dysglycemia necessarily involves a failure in pancreatic insulin
secretion. The present data may suggest that, as well as being more
insulin resistant, TP53INP1-deficient mice also possess b-cells which
may be more susceptible to the effects of global lipid dysregulation.
Interestingly, there are also decreases in miRNAs that regulate
TP53INP1 in human diabetic islets (Kameswaran et al, 2014),
suggesting that over-expression of TP53INP1 may occur in b-cells in
diabetes. At present, it is unclear whether the risk variant at
rs896854 affects the expression of TP53INP1 (or that of other genes
in this locus), in which tissues and in what direction. Future eQTL
studies will be needed to answer this question.
Remarkably, our study provides a mechanism for TP53INP1
function in T2D. Increased predisposition of TP53INP1-deficient
mice to adiposity is mirrored in vitro by a massive LD accumulation
within TP53INP1-deficient cells, also dependent on chronic oxida-
tive stress. At the molecular level, this LD accumulation in
TP53INP1 KO cells is directly correlated with decrease in lipases
expression, but above all with decrease in b-catenin expression
consistent with an increase of PPARc expression. PPARc is a major
player in lipogenesis and LD formation whose expression is inhibited
by the Wnt/b-catenin pathway (Moldes et al, 2003; Sahini & Borlak,
2014). Restoration of TP53INP1 expression decreases PPARc expres-
sion as well as accumulation of LD in close link with dampening of
oxidative stress (Cano et al, 2009). Taken together, these data
provide molecular insights into redox-linked lipid metabolism
defects in the absence of TP53INP1.
Regarding the origin of chronic oxidative stress associated with
TP53INP1 deficiency, we provide data in favor of deregulated mito-
chondrial homeostasis in the absence of TP53INP1. We reveal that
TP53INP1-deficient cells produce high levels of mitochondria-
derived ROS, resulting from both respiratory chain defect and high
number of mitochondria. Furthermore, we show that this latter is
the consequence, at least in part, of impaired PINK/PARKIN mito-
phagy (Novak, 2012) in TP53INP1-deficient cells, consistent with
our previous work reporting a role for TP53INP1 in autophagy
(N’Guessan et al, 2011; Seillier et al, 2012). PINK/PARKIN mito-
phagy involves mitochondrial protein ubiquitination and p62
protein cargo. Interestingly, our laboratory previously provided
evidence that TP53INP1 is able to compete with p62 for interaction
with LC3 thanks to its better LIR affinity (Seillier et al, 2012). Thus,
TP53INP1 could be directly involved in mitophagy by playing the
role of a protein cargo directing mitochondria for degradation to
autophagosomes. Alternatively, accumulation of mitophagic vacu-
oles in the absence of TP53INP1 could mean that TP53INP1 partici-
pates in the completion of PINK/PARKIN-dependent mitophagy.
Data shown in the present work, that is, (i) a direct physical interac-
tion of TP53INP1 with PINK1 and PARKIN, (ii) the influence of
TP53INP1 expression on PINK1 and PARKIN levels in mitochondria
(demonstrated both in loss- and gain-of-function cell models and in
KO livers) and (iii) the subcellular localization of TP53INP1 in mito-
chondria, are in favor of the contribution of TP53INP1 in PINK/
PARKIN-dependent mitophagy.
Finally, it is interesting to note that the TP53INP1 paralog
TP53INP2 (also known as DOR for diabetes and obesity related) is
also involved in MS through its implication in autophagy (Nowak
et al, 2009; Mauvezin et al, 2010; Sala et al, 2014).
To conclude, this work provides a preclinical model of mice
prone to MS. IR establishment in TP53INP1-deficient mice is favored
by chronic oxidative stress, which drives LD accumulation. Further-
more, this work highlights the underlying mechanism by showing
that chronic oxidative stress observed in the absence of TP53INP1
stems from impaired mitophagy of a dysfunctional mitochondrial
pool (graphical abstract shown in Supplementary Fig S8). Therefore,
TP53INP1 mutant mice constitute an original model in which to
study the implication of oxidative stress and autophagy in the devel-
opment of obesity and T2D, two crucial public health issues.
Materials and Methods
Mice
Generation of TP53INP1-deficient (Trp53inp1/) mice backcrossed
on the C57BL/6 parental genetic background and their genotyping
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by PCR were described previously (Gommeaux et al, 2007;
N’Guessan et al, 2011). TP53INP1 WT and KO mice originate from
heterozygous (Trp53inp1+/) pairs. Mice entered protocols at
8 weeks of age and were analyzed between 22 and 26 weeks of age
according to protocols. When not in HFD or GTT/ITT protocols,
mice were weighed at 8 weeks and sacrificed at 22 weeks
(5 months) of age. At sacrifice, organs (liver, gonadal and renal fat
masses) were removed and weighed and then flash-frozen or fixed
in 4% formaldehyde for further analyzes. All mice were kept within
the animal facilities and according to the policies of the Laboratoire
d’Exploration Fonctionnelle de Luminy (Marseilles, France). WT
mice used in Fig 3A, D and E and Supplementary Fig S2C were
C57BL/6J (i.e. C57BL/6 from Jackson Laboratory).
HFD protocol
Male mice (8 week old) were used since (i) weight gain upon
aging of TP53INP1 KO compared to WT males is more
pronounced than females, and (ii) males gain more weight than
females when fed with HFD (Hwang et al, 2010). Mice were
randomly assigned to three cohorts (HFD protocol, HFD protocol
with NAC, HFD protocol followed by GTT and ITT) containing
four groups each (TP53INP1 WT CTRL and HFD and TP53INP1
KO CTRL and HFD). Mice were housed (two mice per cage) under
a 12-h light and 12-h dark cycle. They were fed with either stan-
dard chow (CTRL: Special Diet Services #824050; 20% protein,
10% fat, 70% carbohydrates) or high-fat diet (HFD: Special Diet
Services #824054; 20% protein, 60% fat, 20% carbohydrates) with
ad libitum access to food. During 16 weeks (or 18 weeks for
GTT/ITT cohort), weekly food intake was measured by monitoring
the weight of the remaining food at cage changing, always at the
same daytime moment. Concurrently, mice were weighed. One
cohort was given antioxidant NAC (Sigma-Aldrich, Saint-Quentin
Fallavier, France) at 10 mg/ml (1%) in drinking water during all
protocol. Except for GTT/ITT cohort, glycemia was taken at begin-
ning and end of the protocol using a hand-held glucometer (One-
Touch Ultra; Lifescan, Issy les Moulineaux, France) from blood
sampled from the tail vein of 6-h-fasted mice. At week 16, mice
were sacrificed by cervical dislocation, and organs were weighed
and stored.
Glucose tolerance and insulin tolerance tests (GTT and ITT)
For the GTT/ITT cohort, GTT test was performed at week 16 of HFD
protocol, ITT at week 17, and sacrifice at week 18. Glucose (1 g/kg
body weight, GTT) or insulin (0.70 U/kg body weight, NovoRapid,
Novo Nordisk, Chartres, France, ITT) was injected intraperitone-
ally to 6-h-fasted mice. Glycemia was taken from tail vein blood
sample before and after injection at different time points during 120
(GTT) or 150 (ITT) min. Area under curve (AUC; GTT) and area
above curve (AAC; ITT) were determined using Excel and the trape-
zoidal rule.
Plasma insulin level measurement
Plasma insulin levels were determined using a sensitive rat insulin
RIA kits according to manufacturer instructions (Millipore, Mols-
heim, France).
NADP(H), [Ca2+]c and insulin secretion
Islets were isolated after collagenase digestion of the pancreas from
3-month-old TP53INP1 WT and KO male mice and were used after
an overnight culture in RPMI-1640 (Life Technologies, Cergy
Pontoise, France) supplemented with 10 mM glucose and 10% fetal
bovine serum (FBS). The medium used for the experiments was a
Bicarbonate KRB supplemented with 3 mM glucose. For [Ca2+]c,
NADP(H) and insulin secretion, the experiments were performed on
17 (WT) and 21 (KO) islets as previously reported (Ravier et al,
2014).
Histological analysis
Liver
Formaldehyde-fixed paraffin-embedded liver sections from HFD
protocol mice were deparaffinized and stained with hematoxylin/
eosin. Integrality of mounted stained sections surfaces was viewed
on a Nikon microscope, and representative pictures were shown.
Pancreas
Pancreases from 3-month-old TP53INP1 WT (n = 4) and KO (n = 4)
male mice were spread into flat embedding cassettes, fixed with 4%
paraformaldehyde, paraffin embedded and longitudinally sectioned
through the pancreatic head-to-tail axis (4 lm thickness). Three
pancreatic sections per mouse, separated by at least 100 lm, were
stained with hematoxylin/eosin and scanned using a NanoZoomer
slide scanner (Hamamatsu Photonics, Hamamatsu City, Japan). The
islet numbers were quantified, and the area of each islet was
measured with the NDP.view software, version 1.2.
Cell culture
Cell lines were cultured in DMEM Glutamax medium (Life Technol-
ogies) supplemented with 10% (FBS) in a humidified atmosphere
with 5% CO2 at 37°C. TP53INP1 WT and TP53INP1 KO primary
MEFs were obtained from embryos derived from homozygous
breeding at 14.5 days postcoitum (E14.5) according to standard
procedure. Immortalized MEFs (MEFi) were prepared from primary
MEFs by sequential passages as for 3T3 cell line establishment.
MEFs were cultured in the presence of penicillin (100 mU/ml) and
streptomycin (100 mg/ml). They were used at early passages.
HEK293T and U2OS cell lines were purchased from the American
Type Culture Collection (Manassas, VA, USA). TP53INP1a-inducible
U2OS cells (U2OSi), obtained by stable cotransfection with pVgRXR
and pIND-TP53INP1a-EGFP vectors as previously reported (Gironella
et al, 2007), were cultured in the presence of zeocin (0.05 mg/ml)
and G418 (0.2 mg/ml).
Cell treatments
Cells were plated in medium supplemented or not with 10 mM NAC
and either treated 48 h later (80% confluency) with 1 mM hydrogen
peroxide (H2O2) (Sigma-Aldrich) directly added in culture media or
left untreated. After 1 h, cells were thoroughly rinsed twice with
PBS and incubated 4 h with new culture medium containing or not
5 mM 3-MA (Early autophagic blocker, Sigma-Aldrich), 10 mM
NAC, 10 lM GW9662 (Irreversible PPARc antagonist; Sigma-Aldrich)
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and 50 lM PNU-74654 (Wnt/b-catenin pathway inhibitor; Sigma-
Aldrich).
Induction and transfection
In TP53INP1a-inducible U2OS cells, TP53INP1a-GFP expression
was induced on 70% confluent cells using 10 lM ponasterone A
(Life Technologies) for 24 h. DNA transfections were performed
using FuGENE HD (Promega) according to the manufacturer’s
instructions on 75% confluent cells 24 h before experiment.
Flow cytometry
MEFi were incubated during 10 min at 37°C with 5 lM MitoSOXTM
Red (Life Technologies #M36008) or 200 nM MitoTracker Deep
Red (Life Technologies #M22426) diluted in HBSS (Hank’s buffered
salt solution; Life Technologies). Cells were trypsinized and rinsed
by centrifugation (1,200 g, 5 min) with PBS. They were then
analyzed on a FACSCalibur flow cytometer (BD Biosciences, Le Pont
de Claix, France). Data analysis was performed using FlowJO (Tree-
star, Olten, Switzerland) software.
Transmission electron microscopy (TEM)
MEFi were seeded in 10-cm dishes (7.5 × 106 cells) 48 h before
treatment. Cells were then rinsed twice with PBS and fixed for 1 h
in cacodylate sodium buffer 0.2 M, pH 7.2, containing 2.5% glutar-
aldehyde, 8% paraformaldehyde and 0.01% CaCl2. Samples were
then treated as described previously (Baron Gaillard et al, 2011).
Observations were performed on an EM 912 electron microscope
(Zeiss) at 100-kV acceleration equipped with a BioScan camera
(Model 792; Gatan, Warrendale, PA, USA). Images were acquired
with the Digital Micrograph software (Gatan). Quantification of the
number of mitochondria, mitophagic vacuoles and lipid droplets
normalized by cytoplasmic surface area was done by counting these
structures on 40 images for which surface occupied by cell cyto-
plasm has been determined. Quantification of mean size of mito-
chondria was done by using area of an ellipse formula
(area = longer diameter × smaller diameter × p), longer diameter of
mitochondria being determined on images and smaller diameter
considered as half of longer diameter.
High-resolution respirometry
High-resolution respirometry was performed using a 2-ml chamber
OROBOROS Oxygraph 2K (Oroboros Instruments, Innsbruck,
Austria) at 37°C. Respiration rates were calculated as the time deriv-
ative of oxygen concentration measured in the closed respirometer
and expressed per million viable cells and corrected by non-
mitochondrial oxygen consumption (antimycin A). The amplified
signal was recorded in a computer with online display of the
calibrated oxygen concentration and oxygen flux (DatLab software
for data acquisition and analysis; Oroboros Instruments). Intact
cells (0.5 × 106 cells/ml) were analyzed in their respective bioener-
getic substrate-containing cultivation medium. ROUTINE respiration
(no additions), LEAK respiration (oligomycin-inhibited, 8 lg/ml)
and ETS capacity (maximum non-coupled respiration induced by
stepwise (typically 2–3 steps) titration of carbonyl cyanide
p-(trifluoromethoxy) phenylhydrazone (FCCP), 0.8 mM dissolved in
ethanol) were determined. Oxygen consumption was also measured
on cells permeabilized with digitonin (8 lg/ml) in respiration buffer
(10 mM KH2PO4, 300 mM mannitol, 10 mM KCl, 5 mM MgCl2,
1 mM EGTA and 1 mg/ml BSA fatty acid free) at final cell densities
0.5 × 106 cells per milliliter. Respiration state 3 and 4 (LEAK) and
ETS capacity were measured with pyruvate, malate and succinate (5,
5 and 10 mM, respectively) or palmitoylcarnitine and malate (40 lM
and 5 mM, respectively). Activity of complex IV (cytochrome c
oxidase) was determined by oxygraphy with trimethyl pentanediol
(TMPD) as substrate.
Fluorescence microscopy
Bodipy staining
Since Bodipy fluoresces in green, we used expression vectors encod-
ing TP53INP1 isoforms tagged in red fluorescence. U2OSi cells were
cotransfected by TP53INP1a + b-DsRed-N1 vector (containing
human full-length TP53INP1 cDNAs) or empty pcDNA4/V5-His
vector (Clontech, Saint-Germain-en-Laye, France) 24 h prior experi-
ment. Cells (MEFi or U2OS) plated on glass coverslips in 12-well
plates were treated as indicated and then fixed with 4% paraformal-
dehyde. Cells were washed with PBS and stained with BODIPY
493–503 7.5 lg/ml (Life Technologies #D3922) in PBS during
5 min. Slides were then mounted in ProLong Gold antifade reagent
with DAPI (Invitrogen) for imaging. Fluorescent images were
captured using a Nikon microscope Eclipse 90I.
Mitotracker-LC3 co-staining
MEFi cells were plated on glass coverslips in 12-well plates 48 h
prior experiment. Cells were incubated in a humidified atmo-
sphere with 5% CO2 at 37°C during 15 min with MitoTracker

Red CMXRos 100 nM (Life Technologies #M-7512) diluted in
warmed culture medium. After 2 washes with 1× PBS, cells were
fixed during 15 min at 37°C with warmed 4% paraformaldehyde.
Following fixation, cells were incubated in blocking buffer (3%
BSA, 0.01% saponin in 1× PBS) containing 0.2 M glycine and
10% goat serum for 30 min. Then, cells were incubated 1 h at
room temperature with primary antibody anti-LC3 (PM036-1:500;
MBL, Nanterre, France) diluted in blocking buffer and washed
three times before the addition of secondary antibody (Alexa
Fluor 488 goat anti-rabbit, A-11034-1:500; Invitrogen). After 1 h
of incubation at room temperature, cells were washed three times
and slides were mounted in ProLong Gold antifade reagent with
DAPI (Invitrogen) for imaging. Fluorescent images were captured
using a Zeiss LSM 510 confocal microscope (Carl Zeiss, Le Pecq,
France). Quantification of Mitotracker-LC3-positive puncta
(= mitophagic figures) was done in 10 cells per genotype in three
independent experiments.
Insulin/TP53INP1 co-staining
Insulin and TP53INP1 immunoreactivity were revealed with an anti-
insulin antibody (1:200, DakoCytomation, Ely, UK) and with E12
mAb specific of TP53INP1 (1:100) (Gironella et al, 2007), respec-
tively. Images were captured from mouse pancreatic sections and
single human islet beta cell using a Zeiss Nipkov spinning disk
confocal microscope (Hodson et al, 2013). Base images were
captured and exported as TIFF files; figures were created using
EMBO Molecular Medicine Vol 7 | No 6 | 2015 ª 2015 The Authors
EMBO Molecular Medicine TP53INP1 prevents redox-driven metabolic syndrome Marion Seillier et al
814
Adobe Photoshop 11. No manipulations other than global contrast
and brightness adjustments were performed on images.
Denaturing lysis
Cells were resuspended in denaturing lysis buffer (8 M urea,
0.1 M Na2HPO4/NaH2PO4, 0.01 M Tris–HCl, pH 8.0, 0.5% Triton
X-100). Then, proteins were resolved by SDS–PAGE and
immunoblotted.
Mitochondria isolation
From cells
TP53INP1a-inducible U2OS cells were seeded in 15-cm dishes
(7.5 × 106 cells) 48 h before being collected by scrapping. Mitochon-
dria were isolated according to the manufacturer’s instructions of
Mitochondria Isolation Kit for Cultured Cells (Abcam #ab110171,
Paris, France). Briefly, after one freeze–thaw cycle, pellets from 2
dishes were resuspended in 750 ll Reagent A at 5.0 mg/ml protein
and incubated on ice for 10 min. Cells were then disrupted with a
Dounce homogenizer. After centrifugation (1,000 g, 10 min, 4°C),
supernatants (SN1) were saved. Pellets were resuspended in 750 ll
Reagent B, ruptured with Dounce homogenizer and centrifugated
again. Supernatants (SN2) were collected and added to SN1. Few
microliters of SN1+ SN2 was kept as total protein cell lysates. After
spinning of remaining SN1 + SN2 (12,000 g, 10 min, 4°C), superna-
tants were discarded: pellets were resuspended in 450 ll Reagent C
containing protease inhibitors cocktail (Sigma-Aldrich), forming
mitochondrial lysates.
From tissue
Six TP53INP1 WT and six KO male mice (3 month old) were sacri-
ficed and their livers sampled. Mitochondrial lysates were extracted
from 300 mg of fresh liver according to the manufacturer’s instruc-
tions of Mitochondria Isolation Kit for Tissue (Abcam #ab110169).
A small volume of lysates before first high-speed centrifugation
(12,000 g) was kept as total protein lysates.
Coprecipitation assay
HEK293T cells in six-well plates were cotransfected by TP53INP1a-
or b-NTAP vector (containing human full-length TP53INP1 cDNAs)
or empty pNTAP vector (Agilent, Massy, France). After 24 h of
transfection, cells were harvested by scraping and lysed and protein
complexes were purified using streptavidin-containing resin accord-
ing to the manufacturer’s instructions of InterPlay Mammalian TAP
Purification Kit (Agilent). Then, proteins were resolved by SDS–
PAGE and immunoblotted.
Immunoblotting
After boiling in Laemmli buffer (20 mM Tris pH 6.8, 2 M b-mercapto-
ethanol, SDS 9%, glycerol 30%), proteins from total lysates,
mitochondrial lysates or co-immunoprecipitations were resolved by
SDS–PAGE, transferred to polyvinylidene fluoride membrane,
blocked in 5% non-fat milk in phosphate-buffered saline (PBS)/
Tween-20, blotted and developed with antibodies specific for ATGL
(2439-1:1,000; Cell Signaling Technology, Saint-Quentin-en-Yvelines,
France), BNIP3 (ab10433-1:250; Abcam), BNIP3L/NIX (ab8399-
1:1,000; Abcam), CPT1A (ab128568-1:800; Abcam), CPT1B
(ab104662-1:800; Abcam), MGLL (ab119777-1:1,000; Abcam),
PARKIN (ab15954-1:1,050; Abcam), PGC-1a (sc13067-1:200; Santa
Cruz Biotechnology, Heidelberg, Germany), PINK1 (BC100-494-
1:500; Novus Biologicals, Montluc¸on, France), PPARc (sc72-73-
1:1,250; Santa Cruz Biotechnology), TP53INP1 [rat monoclonal anti-
body generated in our laboratory, clone F8 (Saadi et al, 2013),
2 lg/ml], VDAC1 (ab14734-1:2,500; Abcam), b-catenin (sc1496-
1:500; Santa Cruz Biotechnology) or b-tubulin (T4026-1:4,000;
Sigma-Aldrich). Secondary antibodies were purchased from Santa
Cruz Biotechnology: anti-rabbit horseradish peroxidase (HRP)
conjugate (sc-2004-1:4,000) and anti-mouse HRP conjugate (sc-
2005-1:6,000). Immunoblots were developed using the Immobilon
Western Chemiluminescent HRP Substrate (Millipore). Chemilumi-
nescence was detected using Fusion FX7 device (Fisher Bioblock
Scientific, Illkirch, France). The experiments for the immunoblotting
were performed at least three times with comparable results.
Real-time quantitative PCR
Total RNAs from islets and exocrine pancreas (from mouse and rat)
were extracted and DNase-treated using the RNeasy microkit from
Qiagen, according to the manufacturer’s instructions. Total RNAs
from other tissues (spleen, liver) and b-cell lines were extracted
using RNAnow (Ozyme) and treated with DNase (Ambion) accord-
ing to the manufacturers’ instructions. For HFD islets, C57BL/6J
female mice purchased from Charles River (France) were fed either
with a standard normal diet (ND, 5 kcal % fat) or a HFD containing
lard (45 kcal % fat; D12451; Research Diets, New Brunswick, NJ,
USA) from 8 weeks for 23 weeks. Islets were isolated after collage-
nase digestion of the pancreas (Broca et al, 2009). The quality of the
islet preparations was validated by measuring the expression of
Insulin and Elastase 3b by RT–qPCR in both exocrine and islet RNAs.
The presence of exocrine tissue in the islets was < 5% (mean 1.7%,
not shown). INS-1E and MIN6 cells were grown and maintained as
described previously (Broca et al, 2009; Quoyer et al, 2010).
Reverse transcription was performed on total RNA using random
hexamer oligonucleotides and MoMuLV-RT (Invitrogen). Real-time
PCR amplification was performed in duplicate, using the 7500
System (Applied Biosystems) and according to the manufacturer’s
instructions. The sequences of the primers used were as follows:
Trp53inp1: GTTGACTTCATAGATACCTGCCC/GTGTGCTCTGCT-
GAGGACTC which were validated both on rat and mouse cDNAs;
Tubb2: CAAGGCTTTCCTGCACTGGT/AACTCCATCTCGTCCATGCC,
which were validated both on rat and mouse cDNAs; mHprt: GCAG-
TACAGCCCCAAAATGG/GGTCCTTTTCACCAGCAAGCT; and rHprt:
CAAAATGGTTAAGGTTGCAAGCT/AACACTTCGAGAGGTCCTTTT-
CAC. The level of expression of each gene X was normalized to the
geometric mean of the expression levels of two housekeeping genes
(Hprt and Tubb2) according to the formula: X/geometric mean
(Hprt, Tubb2) = 2(Ct(X)  arithmetic mean (Ct(Hprt),Ct(Tubb2))), where Ct
is the threshold cycle.
Statistical analysis
Results are expressed as the mean  SEM of results from at least
two independent experiments. Statistical analyses were mainly
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performed via Student’s t-tests except Mann–Whitney U-tests for
Fig 6. P < 0.05 was considered as significant.
Human studies
Morbidly obese patients (n = 39) were recruited through the Depart-
ment of Digestive Surgery and Liver Transplantation (Nice Hospital)
where they underwent bariatric surgery for their morbid obesity.
Bariatric surgery was indicated for these patients in accordance with
French guidelines. Exclusion criteria were presence of a hepatitis B
or hepatitis C infection, excessive alcohol consumption (> 20 g/day)
or another cause of chronic liver disease as previously described
(Anty et al, 2006; Bekri et al, 2006; Bertola et al, 2009). The
characteristics of the study groups are described in Supplementary
Table S2. Before surgery, fasting blood samples were obtained
and used to measure alanine amino transferase (ALT), glucose,
insulin, HDL cholesterol, LDL cholesterol and triglycerides. Insulin
resistance was calculated using the homeostatic model assessment
(HOMA-IR) index (Wallace et al, 2004). Surgical liver biopsies
were obtained during surgery, and no ischemic preconditioning
had been performed. Histopathological analysis was performed
to evaluate hepatic steatosis (0, < 5%; 1, 5–30%; 2, > 30–60%;
3, > 60%).
Total liver RNA was extracted from human tissues using the
RNeasy Mini Kit (Qiagen, Contraboeuf, France) and treated with Turbo
DNA free (Applied Biosystems, Contraboeuf, France) following the
manufacturer’s protocol. The quantity and quality of the RNA were
determined using the Agilent 2100 Bioanalyser with RNA 6000 Nano
Kit (Agilent Technologies). Total RNA (1 lg) was reverse-transcribed
with a High-Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems). Real-time quantitative PCR was performed in duplicate for
each sample using the ABI Step One Fast Real-Time PCR System
(Applied Biosystems) as previously described (Kleiner et al, 2005).
TaqMan gene expression assays were purchased from Applied Biosys-
tems: RPLP0 (Hs99999902_m1) and TP53INP1 (Hs01003820_m1).
Gene expression was normalized to the housekeeping gene human
RPLP0 (ribosomal phosphoprotein large P0) calculated based on the
comparative cycle threshold Ct method (2DDCt). Results are expressed
as the mean  SEM. Statistical significance of differential human gene
expression between two study groups was determined using the
non-parametric Mann–Whitney U-test with the DCt of each group.
Correlations were analyzed using the Spearman’s rank correlation test.
P < 0.05 was considered as significant.
Study approval
Care and manipulation of mice were performed in accordance with
national and European legislation on animal experimentation and
were approved by the Aix-Marseille University Institutional Animal
Care and Use Committee. Regarding human study, all subjects gave
their informed written consent to participate in this study in accor-
dance with French legislation regarding Ethics and Human Research
(Huriet-Serusclat law). The ‘Comite´ Consultatif de Protection des
Personnes dans la Recherche Biome´dicale de Nice’ approved the
study (07/04:2003, No 03.017).
Supplementary information for this article is available online:
http://embomolmed.embopress.org
Acknowledgements
We are grateful to the IBDML electron microscopy facilities (PICsL platform), to
Laurence Borge (cell culture platform of Marseille/Luminy), to Karim Sari, Régis
Vitestelle and Romain Magro for assistance with the use of the animal housing
facility, to Fabrice Gianardi and Gilles Warcollier for assistance with the use of
the Laboratoire d’Exploration Fonctionnelle de Luminy, to Marie-Noëlle Lavaut
and Stéphane Garcia for support in histological analysis, and to Lionel Chasson
(Histology Platform of CIML) for support in confocal microscopy analyses. We
also thank Rose-Patricia Spoto for preparation of tail of mice DNA for genotyp-
ing, Thomas Bonacci for help in Western blotting, Jacques Nunès and Marie-
Christine Alessi for advices in HFD protocol, and Mathias Chamaillard and
Fatima Mechta-Grigoriou for helpful discussions. The authors were supported
by Institut National de la Santé et de la Recherche Médicale, Centre National
de la Recherche Scientifique, Institut National du Cancer, Association pour la
Recherche sur le Cancer and La Ligue Nationale contre le Cancer. This work
was also supported by grants from the University of Nice, the Programme
Hospitalier de Recherche Clinique (Centre Hospitalier Universitaire of Nice),
charities (Association Française pour l’Etude du Foie (AFEF/LFB) to PG, Euro-
pean Foundation for the study of Diabetes EFSD/Lilly to PG) and by the French
Government (National Research Agency, ANR) through the ‘Investments for the
Future’ LABEX SIGNALIFE: program reference #ANR-11-LABX-0028-01. G.A.R.
was supported by Wellcome Trust Senior Investigator (WT098424AIA), MRC
Programme (MR/J0003042/1) and Royal Society Wolfson Research Merit
Awards. M.S. was supported by Association pour la Recherche sur le Cancer.
A.C. and S.S. thank the NACRe (Réseau National Alimentation Cancer
Recherche) Network for collaboration linking.
The paper explained
Problem
The gene encoding tumor protein 53-induced nuclear protein 1
(TP53INP1) is a target of the tumor suppressor p53 and displays itself
a tumor suppressor activity. TP53INP1 contributes to maintain cellular
homeostasis in response to stress, in synergy with p53. Interestingly,
the tumor suppressor activity of TP53INP1 is associated with its anti-
oxidant function, shedding light in the link between the oxidative
stress response and carcinogenesis. In addition, (i) TP53INP1 is
involved in autophagy, a crucial catabolism process for cell homeosta-
sis, and (ii) a genome-wide association study (GWAS) published in
2010 identified TP53INP1 as a new type 2 diabetes susceptibility locus,
but a pathological mechanism was not identified. In this context, this
study further investigates the importance of TP53INP1 in cell metabo-
lism regulation, associated with its implication in autophagy and
redox homeostasis.
Results
In this paper, we demonstrate that TP53INP1 is involved in the
prevention of redox-driven obesity, which promotes insulin resistance,
and thus type 2 diabetes. Furthermore, we unveil the impact of
TP53INP1 on mitochondrial homeostasis, both quantitatively and
qualitatively, as well as the central role of mitophagy alterations in
chronic oxidative stress observed in the absence of TP53INP1. Thus,
we provide a mechanism of TP53INP1 function in redox-dependent
metabolism homeostasis.
Impact
TP53INP1 is a novel molecular actor in obesity and type 2 diabetes,
thus being a promising target in prevention or therapy of metabolic
syndrome. Thus, this study provides a useful preclinical model of mice
prone to metabolic alterations.
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